Key Points - The company announced the interest payment schedule for its convertible bonds, "东亚转债," which will begin on July 7, 2025 [1][2] - The total amount raised from the issuance of the convertible bonds is RMB 690 million, with a maturity period of 6 years and a tiered interest rate structure [1][2] - The bond's interest rates are set at 0.20% for the first year, increasing to 2.50% by the sixth year [1][2] - The bond's conversion price was adjusted from RMB 24.95 to RMB 20.60, and subsequently to RMB 20.28 due to profit distribution [2] - The interest payment for the second year will be calculated based on a rate of 0.40%, resulting in a payment of RMB 0.40 per bond before tax [4][5] - The bondholders will receive their interest payments through the China Securities Depository and Clearing Corporation Limited, and tax obligations will be handled by the payment institutions [4][5] - Non-resident enterprises holding the bonds are exempt from corporate income tax on the interest income until December 31, 2025 [5]

Group 1 - The meeting of the fourth supervisory board of Zhejiang Dongya Pharmaceutical Co., Ltd. was held on May 30, 2025, in accordance with relevant laws and regulations [1][2] - The supervisory board approved the proposal to postpone the investment project funded by convertible bonds, stating that the decision was made based on the actual situation of the project and did not harm the interests of shareholders or the company [1][2] - The voting results showed unanimous support for the proposal, with 3 votes in favor and no votes against or abstentions [2]